Rate My Professor Vino Kavarthapol Jayaraman

Dr Vino Kavarthapol Jayaraman is a Senior Lecturer in the Curtin Medical School within the Faculty of Health Sciences at Curtin University. He holds a position under the Office of the Provost and contributes to medical education in Perth, Australia. His professional activities extend to clinical practice, with affiliations at Fiona Stanley Hospital, where he engages in patient care and research related to renal medicine.

Dr Jayaraman has presented research at the Australia and New Zealand Society of Nephrology (ANZSN) Congress in August 2025. He co-authored the poster 'Atypical Case of C3-Dominant Crescentic Glomerulonephritis: A Diagnostic Challenge between C3 Glomerulopathy and Infection-Related GN' with Dr Isra Iftikhar and Dr Zhan Lim. The case involved a 78-year-old female presenting with lower limb cellulitis, fever, rigors, and raised inflammatory markers. Initially normal kidney function progressed to acute kidney injury with haemoproteinuria. Kidney biopsy revealed diffuse crescentic glomerulonephritis with 95% cellular crescents, focal endocapillary hypercellularity, and dominant mesangial C3 deposits. Immunological tests showed normal complements, elevated anti-streptolysin-O titre, and negative autoantibodies. Treatment included pulse methylprednisolone, but the patient remained dialysis-dependent, with genetic testing for complement dysregulation pending. This work underscores the complexities in diagnosing overlapping glomerular pathologies. Additionally, he co-authored 'Ustekinumab Induced IgA Nephropathy' with Dr Ben Tomlinson, reporting the first Australian case in a 57-year-old male with psoriasis treated with ustekinumab for 18 months. The patient developed declining renal function (peak creatinine 143 μmol/L), haemoproteinuria (urine ACR 128.1), hypertension, and obesity. Renal biopsy demonstrated glomerulomegaly, mild mesangial hypercellularity, and mesangial deposits of IgA and C3c, consistent with IgA nephropathy. Serum ANA was positive; management involved ustekinumab cessation, potential short-course steroids, and alternative psoriasis treatments. These contributions highlight his focus on rare renal presentations and drug-induced kidney diseases.